Assessing the ecological resilience of Ebola virus in Africa and potential influencing factors based on a synthesized model.

PLoS Negl Trop Dis

Department of Epidemiology, The Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, The Shaanxi Provincial Key Laboratory of Environmental Health Hazard Assessment and Protection, The Shaanxi Provincial Key Laboratory of Free Radical Biology and Medicine, School of Public Health, The Fourth Military Medical University, Xi'an, China.

Published: February 2025

Background: The Ebola epidemic has persisted in Africa since it was firstly identified in 1976. However, few studies have focused on spatiotemporally assessing the ecological adaptability of this virus and the influence of multiple factors on outbreaks. This study quantitatively explores the ecological adaptability of Ebola virus and its response to different potential natural and anthropogenic factors from a spatiotemporal perspective.

Methodology: Based on historical Ebola cases and relevant environmental factors collected from 2014 to 2022 in Africa, the spatiotemporal distribution of Ebola adaptability is characterized by integrating four distinct ecological models into one synthesized spatiotemporal framework. Maxent and Generalized Additive Models were applied to further reveal the potential responses of the Ebola virus niche to its ever-changing environments.

Findings: Ebola habitats appear to aggregate across the sub-Saharan region and in north Zambia and Angola, covering approximately 16% of the African continent. Countries presently unaffected by Ebola but at increasing risk include Ethiopia, Tanzania, Côte d'Ivoire, Ghana, Cameroon, and Rwanda. In addition, among the thirteen key influencing factors, temperature seasonality and population density were identified as significantly influencing the ecological adaptability of Ebola. Specifically, those regions were prone to minimal seasonal variations in temperature. Both the potential anthropogenic influence and vegetation coverage demonstrate a rise-to-decline impact on the outbreaks of Ebola virus across Africa.

Conclusions: Our findings suggest new ways to effectively respond to potential Ebola outbreaks in Sub-Saharan Africa. We believe that this integrated modeling approach and response analysis provide a framework that can be extended to predict risk of other worldwide diseases from a similar epidemic study perspective.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11805440PMC
http://dx.doi.org/10.1371/journal.pntd.0012843DOI Listing

Publication Analysis

Top Keywords

ebola virus
16
ecological adaptability
12
ebola
11
assessing ecological
8
influencing factors
8
adaptability ebola
8
virus
5
potential
5
factors
5
ecological resilience
4

Similar Publications

Cases of high-consequence infectious diseases identified in the UK, 1962-2023.

J Med Microbiol

March 2025

NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, UK.

The management of patients with acute infectious diseases can present significant challenges, especially if the causative agent has a propensity for person-to-person transmission. In such cases, effective patient management is dependent on both rapid identification of disease and the provision of necessary medical care while adhering to suitable infection prevention and control measures to reduce the potential for onwards transmission. The UK has operated a defined system for managing patients with high-consequence infectious diseases (HCIDs) since the 1970s, when protocols were first implemented following the first descriptions of several viral haemorrhagic fever diseases, including Marburg virus disease, Lassa fever and Ebola virus disease (EVD).

View Article and Find Full Text PDF

Background: Uganda reported an outbreak of Ebola virus disease (EVD) in 2022. As part of the outbreak response, government and partners promoted community engagement, which seeks to involve communities in the design, implementation and evaluation of interventions to raise awareness, build trust between communities and partners and create ownership of interventions. This study, therefore, explored barriers to community engagement during the 2022-2023 EVD outbreak response in Uganda.

View Article and Find Full Text PDF

Structural basis for Ebola virus nucleocapsid assembly and function regulated by VP24.

Nat Commun

March 2025

Laboratory of Ultrastructural Virology, Institute for Life and Medical Sciences, Kyoto University, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

The Ebola virus, a member of the Filoviridae family, causes severe hemorrhagic fever in humans. Filamentous virions contain a helical nucleocapsid responsible for genome transcription, replication, and packaging into progeny virions. The nucleocapsid consists of a helical nucleoprotein (NP)-viral genomic RNA complex forming the core structure, to which VP24 and VP35 bind externally.

View Article and Find Full Text PDF

VITALdb: to select the best viroinformatics tools for a desired virus or application.

Brief Bioinform

March 2025

Computational Biology and Translational Bioinformatics (CBTB) Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.

The recent pandemics of viral diseases, COVID-19/mpox (humans) and lumpy skin disease (cattle), have kept us glued to viral research. These pandemics along with the recent human metapneumovirus outbreak have exposed the urgency for early diagnosis of viral infections, vaccine development, and discovery of novel antiviral drugs and therapeutics. To support this, there is an armamentarium of virus-specific computational tools that are currently available.

View Article and Find Full Text PDF

Unlabelled: The Marburg virus (MARV), a member of the family Filoviridae, is a highly pathogenic virus causing severe hemorrhagic fever with extremely high mortality in humans and non-human primates. The MARV exhibits clinical and epidemiological features almost identical to those of the Ebola virus, no licensed vaccines or antiviral treatments have been developed yet for MARV. However, only a few treatments that remain uncertain of the disease are available to help bring a case for a new therapeutic approach.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!